Serum fructosamine and glycated albumin and risk of mortality and clinical outcomes in hemodialysis patients

Diabetes Care

Volumn 36, Issue 6, 2013, Pages 1522-1533

  Shafi, Tariq ^a,b   Sozio, Stephen M ^a,b   Plantinga, Laura C ^c   Jaar, Bernard G ^a,b,d,e   Kim, Edward T ^f   Parekh, Rulan S ^a,d,g   Steffes, Michael W ^h   Powe, Neil R ^a,d,i   Coresh, Josef ^a,b,c,d   Selvin, Elizabeth ^a,b,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c EMORY UNIVERSITY   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e NEPHROLOGY CENTER OF MARYLAND   (United States)

^f Diablo Nephrology Medical Group   (United States)

^g HOSPITAL FOR SICK CHILDREN   (Canada)

^h UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FRUCTOSAMINE; GLYCOSYLATED ALBUMIN;

ADULT; AGE; ARTICLE; CARDIOVASCULAR DISEASE; CAUCASIAN; CAUSE OF DEATH; CLINICAL FEATURE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEMODIALYSIS; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SEPSIS;

ADULT; AGED; CARDIOVASCULAR DISEASES; FEMALE; FRUCTOSAMINE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; SERUM ALBUMIN;

EID: 84878253841     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-1896     Document Type: Article

References (30)

1. U.S. Renal Data System. USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2011
2. Mehrotra R, Kalantar-Zadeh K, Adler S. Assessment of glycemic control in dialysis patients with diabetes: glycosylated hemoglobin or glycated albumin? Clin J Am Soc Nephrol 2011;6:1520-1522
3. Freedman BI, Shenoy RN, Planer JA, et al. Comparison of glycated albumin and hemoglobin A1c concentrations in diabetic subjects on peritoneal and hemodialysis. Perit Dial Int 2010;30:72-79
4. Peacock TP, Shihabi ZK, Bleyer AJ, et al. Comparison of glycated albumin and hemoglobin A(1c) levels in diabetic subjects on hemodialysis. Kidney Int 2008;73:1062-1068 (Pubitemid 351543905)
5. Armbruster DA. Fructosamine: structure, analysis, and clinical usefulness. Clin Chem 1987;33:2153-2163
6. Koga M, Kasayama S. Clinical impact of glycated albumin as another glycemic control marker. Endocr J 2010;57:751-762
7. Ricks J, Molnar MZ, Kovesdy CP, et al. Glycemic control and cardiovascular mortality in hemodialysis patients with diabetes: a 6-year cohort study. Diabetes 2012;61:708-715
8. Williams ME, Lacson E Jr, Teng M, Ofsthun N, Lazarus JM. Hemodialyzed type I and type II diabetic patients in the US: characteristics, glycemic control, and survival. Kidney Int 2006;70:1503-1509 (Pubitemid 44527322)
9. Powe NR, Klag MJ, Sadler JH, et al. Choices for healthy outcomes in caring for end stage renal disease. Semin Dial 1996;9:9-11 (Pubitemid 126670719)
10. Longenecker JC, Klag MJ, Marcovina SM, et al. High lipoprotein(a) levels and small apolipoprotein(a) size prospectively predict cardiovascular events in dialysis patients. J Am Soc Nephrol 2005;16:1794-1802 (Pubitemid 41716486)
11. Miskulin DC, Meyer KB, Athienites NV, et al. Comorbidity and other factors associated with modality selection in incident dialysis patients: the CHOICE Study. Choices for Healthy Outcomes in Caring for End-Stage Renal Disease. Am J Kidney Dis 2002;39:324-336 (Pubitemid 34174255)
12. Athienites NV, Miskulin DC, Fernandez G, et al. Comorbidity assessment in hemodialysis and peritoneal dialysis using the index of coexistent disease. Semin Dial 2000;13:320-326
13. Liu Y, Coresh J, Eustace JA, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 2004;291:451-459 (Pubitemid 38129749)
14. Singer JD, Willett JB. Applied Longitudinal Data Analysis. New York, NY, Oxford University Press, 2003
15. Kalantar-Zadeh K, Kopple JD, Regidor DL, et al. A1C and survival in maintenance hemodialysis patients. Diabetes Care 2007;30:1049-1055 (Pubitemid 46684623)
16. Duong U, Mehrotra R, Molnar MZ, et al. Glycemic control and survival in peritoneal dialysis patients with diabetes mellitus.Clin J Am Soc Nephrol 2011;6:1041-1048
17. Freedman BI, Andries L, Shihabi ZK, et al. Glycated albumin and risk of death and hospitalizations in diabetic dialysis patients. Clin J Am Soc Nephrol 2011;6: 1635-1643
18. Shurraw S, Majumdar SR, Thadhani R, Wiebe N, Tonelli M; Alberta Kidney Disease Network. Glycemic control and the risk of death in 1,484 patients receiving maintenance hemodialysis. Am J Kidney Dis 2010;55:875-884
19. Freedman BI. A critical evaluation of glycated protein parameters in advanced nephropathy: a matter of life or death: time to dispense with the hemoglobin A1C in end-stage kidney disease. Diabetes Care 2012;35:1621-1624
20. Kalantar-Zadeh K. A critical evaluation of glycated protein parameters in advanced nephropathy: a matter of life or death: A1C remains the gold standard outcome predictor in diabetic dialysis patients. Counterpoint. Diabetes Care 2012;35:1625-1628
21. Kim S, Min WK, Chun S, Lee W, Park HI. Glycated albumin may be a possible alternative to hemoglobin A1c in diabetic patients with anemia. Clin Chem Lab Med 2011;49:1743-1747
22. Shima K, Chujo K, Yamada M, Komatsu M, Noma Y, Mizuguchi T. Lower value of glycated haemoglobin relative to glycaemic control in diabetic patients with endstage renal disease not on haemodialysis. Ann Clin Biochem 2012;49:68-74
23. Ansari A, Thomas S, Goldsmith D. Assessing glycemic control in patients with diabetes and end-stage renal failure. Am J Kidney Dis 2003;41:523-531 (Pubitemid 36278368)
24. Kouzuma T, Uemastu Y, Usami T, Imamura S. Study of glycated amino acid elimination reaction for an improved enzymatic glycated albumin measurement method. Clin Chim Acta 2004;346:135-143 (Pubitemid 38901044)
25. Inaba M, Okuno S, Kumeda Y, et al.; Osaka CKD Expert Research Group. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol 2007;18:896-903 (Pubitemid 46434506)
26. Ichikawa H, Nagake Y, Takahashi M, et al. What is the best index of glycemic control in patients with diabetes mellitus on hemodialysis? Nippon Jinzo Gakkai Shi 1996;38:305-308 (Pubitemid 126496398)
27. Mittman N, Desiraju B, Fazil I, et al. Serum fructosamine versus glycosylated hemoglobin as an index of glycemic control, hospitalization, and infection in diabetic hemodialysis patients. Kidney Int Suppl 2010;S41-S45
28. Fukuoka K, Nakao K, Morimoto H, et al. Glycated albumin levels predict long-term survival in diabetic patients undergoing haemodialysis. Nephrology (Carlton) 2008;13:278-283 (Pubitemid 351668328)
29. Selvin E, Ning Y, Steffes MW, et al. Glycated hemoglobin and the risk of kidney disease and retinopathy in adults with and without diabetes. Diabetes 2011;60:298-305
30. Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. NEngl J Med 2010;362:800-811